The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device

Baker, Alexander N.; Richards, Sarah‐Jane; Guy, Collette S.; Congdon, Thomas R.; Hasan, Muhammad; Zwetsloot, Alexander J.; Gallo, Angelo; Lewandowski, Józef; Stansfeld, Phillip J.; Straube, Anne; Walker, Marc; Chessa, S.; Pergolizzi, Giulia; Dedola, Simone; Field, Robert A.; Gibson, Matthew I.

doi:10.1021/acscentsci.0c00855

Cited by 261 publications

(288 citation statements)

References 52 publications

(88 reference statements)

Supporting

Mentioning

282

Contrasting

Unclassified

Order By: Relevance

“…As high purity was required, all glycans were subjected to a two-step purication (gel ltration and ash or anion-exchange chromatography). In total, eight uorinated disaccharides (16)(17)(18)(19)(20)(21)(22)(23) bearing azidopropyl linkers were prepared, in addition to lacto-N-biose derivative (15), in isolated yields ranging from 25-76%.…”

Section: Resultsmentioning

confidence: 99%

Introducing affinity and selectivity into galectin-targeting nanoparticles with fluorinated glycan ligands

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Introducing affinity and selectivity into galectin-targeting nanoparticles with fluorinated glycan ligands

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Baker et al [31] reported the synthesis of polymerstabilized multivalent gold nanoparticles bearing sialic acid derivative and their interaction with spike glycoprotein. It was observed that α, N-acetylneuraminic acid binds strongly Table 1.…”

Section: Nano-based Detection Methodsmentioning

confidence: 99%

“…Lateral flow assay for virus using glycan capture units (adapted from Baker et al[31]; reuse is permitted under CC BY-NC 4.0 license).…”

mentioning

confidence: 99%

Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints

Rai

Bonde

Yadav

et al. 2020

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: COVID-19 pandemic has been declared as a global emergency by the World Health Organization which has mounted global pressure on the healthcare system. The design and development of rapid tests for the precise and early detection of infection are urgently needed to detect the disease and also for bulk screening of infected persons. The traditional drugs moderately control the symptoms, but so far, no specific drug has been discovered. The prime concern is to device novel tools for rapid and precise diagnosis, drug delivery, and effective therapies for coronavirus. In this context, nanotechnology offers novel ways to fight against COVID-19. Area covered: This review includes the use of nanomaterials for the control of COVID-19. The tools for diagnosis of coronavirus, nano-based vaccines, and nanoparticles as a drug delivery system for the treatment of virus infection have been discussed. The toxicity issues related to nanoparticles have also been addressed. Expert opinion: The research on nanotechnology-based diagnosis, drug delivery, and antiviral therapies is at a preliminary stage. The antiviral nanomedicine therapies are cost-effective and with high quality. Nanoparticles are a promising tool for prevention, diagnosis, antiviral drug delivery, and therapeutics, which may open up new avenues in the treatment of COVID-19.

show abstract

“…Applying these characteristics has the advantage of building a low-cost detection platform that can be detected in less than 30 minutes with a lateral flow diagnostic device. 277 …”

Section: Application Of Nanotechnology In Covid-19 Therapeuticsmentioning

confidence: 99%

Application of Nanotechnology in the COVID-19 Pandemic

Yang¹

2021

IJN

View full text Add to dashboard Cite

COVID-19, caused by SARS-CoV-2 infection, has been prevalent worldwide for almost a year. In early 2000, there was an outbreak of SARS-CoV, and in early 2010, a similar dissemination of infection by MERS-CoV occurred. However, no clear explanation for the spread of SARS-CoV-2 and a massive increase in the number of infections has yet been proposed. The best solution to overcome this pandemic is the development of suitable and effective vaccines and therapeutics. Fortunately, for SARS-CoV-2, the genome sequence and protein structure have been published in a short period, making research and development for prevention and treatment relatively easy. In addition, intranasal drug delivery has proven to be an effective method of administration for treating viral lung diseases. In recent years, nanotechnology-based drug delivery systems have been applied to intranasal drug delivery to overcome various limitations that occur during mucosal administration, and advances have been made to the stage where effective drug delivery is possible. This review describes the accumulated knowledge of the previous SARS-CoV and MERS-CoV infections and aims to help understand the newly emerged SARS-CoV-2 infection. Furthermore, it elucidates the achievements in developing COVID-19 vaccines and therapeutics to date through existing approaches. Finally, the applicable nanotechnology approach is described in detail, and vaccines and therapeutic drugs developed based on nanomedicine, which are currently undergoing clinical trials, have presented the potential to become innovative alternatives for overcoming COVID-19.

show abstract

The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device

Cited by 261 publications

References 52 publications

Introducing affinity and selectivity into galectin-targeting nanoparticles with fluorinated glycan ligands

Introducing affinity and selectivity into galectin-targeting nanoparticles with fluorinated glycan ligands

Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints

Application of Nanotechnology in the COVID-19 Pandemic

Contact Info

Product

Resources

About